Laboratory assessment of osteoporosis;Die rolle des labors in der diagnostik und verlaufskontrolle der osteoporose

Therapeutische Umschau

Volumn 65, Issue 9, 2008, Pages 513-518

  Kraenzlin, Marius E ^a,b,d   Anliker, Markus ^c   Griesmacher, Andrea ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Endokrinologische Praxis und Labor   (Switzerland)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; CREATININE; DEOXYPYRIDINOLINE; GAMMA GLUTAMYLTRANSFERASE; GONADORELIN AGONIST; MATRIX METALLOPROTEINASE; OSTEOCALCIN; PHOSPHATE; PYRIDINOLINE; THYROTROPIN;

ANOREXIA NERVOSA; BONE DENSITY; CHRONIC KIDNEY FAILURE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING SYNDROME; DIABETES MELLITUS; DRUG INDUCED DISEASE; EHLERS DANLOS SYNDROME; FRAGILITY FRACTURE; HOMOCYSTINURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCIURIA; HYPERCORTISOLISM; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; HYPERTHYROIDISM; HYPOGONADISM; IMMOBILIZATION; LABORATORY TEST; LACTOSE INTOLERANCE; MALABSORPTION; MALNUTRITION; MARFAN SYNDROME; MASTOCYTOSIS; MULTIPLE MYELOMA; ORGAN TRANSPLANTATION; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; THALASSEMIA;

BIOLOGICAL MARKERS; FRACTURES, SPONTANEOUS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 52349118514     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-930.65.9.513     Document Type: Review

References (34)

1. DVO. DVO Leitlinie 2006: Prophylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr. www dvo-osteologieorg. 2006.
2. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and managment of osteoporosis in Canada. CMAJ 2002; 167 (10 suppl.): S1-S34.
3. Seeman E. Invited Review: Pathogenesis of osteoporosis. J Appl Physiol 2003; 95: 2142-51.
4. Meier C, Handelsman DJ, Seibel MJ. Endocrine regulation of bone turnover in men. Clin Endocrinol 2005; 62: 603-16.
5. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006; 12: 436-45.
6. Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol 2005; 19: 1021-37.
7. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77: 453-68.
8. Kraenzlin ME, Meier C. Diagnostik und Therapie der Osteoporose (Teil 1). Swiss Medical Forum 2006; 6: 712-7.
9. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134: 561-8.
10. Jamal SA, Leiter RE, Bayoumi AM, Bauer DC, Cummings SR. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int 2005; 16: 534-40.
11. Stenson WF, Newberry R, Lorenz R, Baldus C, Civitelli R. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005; 165: 393-9.
12. O'Leary C, Feighery C, Feighery A, Quane K, Shanahan F, Molloy M, et al. The prevalence of coeliac disease among female subjects having bone densitometry. Ir J Med Sci 2002; 171: 145-7.
13. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskel Neuron Interact 2004; 4: 50-63.
14. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003; 32: 83-vii.
15. Kraenzlin ME. Practical use of biochemical markers of bone turnover. Ann Endocrinol (Paris) 2006; 67: 155-6.
16. Kraenzlin ME, Seibel M. Measurement of biochemical markers of bone resorption. In: Seibel M, Robins S, Bilezikian J, eds. Dynamics in bone and cartilage metabolism. 2 ed. Academic Press; 2006: 541-64.
17. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051-6.
18. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 2005; 20: 579-87.
19. Johnell O, Odén A, De Laet C, Delmas PD, Kanis JA. Biochemical Indices of Bone Turnover and the Assessment of Fracture Probability. Osteoporos Int 2002; 13: 523-6.
20. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281-9.
21. Wasnich RD, Miller P. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6.
22. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586-92.
23. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004; 34: 599-604.
24. Delmas P. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000; 11 (Suppl. 6): 66-76.
25. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006; 119: S25-S31.
26. Briot K, Roux C. What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring? Best Pract Res Clin Rheumatol 2005; 19: 951-64.
27. Roux C, Garnero P, Thomas T, Sabatier JP, Orcel P, Audran M. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 2005; 72: 26-31.
28. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005; 3: 103-10.
29. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12: 922-30.
30. Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007; 22: 1656-60.
31. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19: 1250-8.
32. Harrington JT, Ste-Marie L-G, Brandi ML, Civitelli R, Fardellone P, Grauer A, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74: 129-35.
33. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006; 91: 1370-5.
34. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20: 962-70.